ClinicalTrials.gg
RecruitingNCT06288165LSSRRUpdated Mar 1, 2024

Lower Silesia Sinus Reducer Registry

An observational study in Safety Issues and Efficacy, Self, sponsored by Regional Cardiology Center, The Copper Health Centre (MCZ),. Recruiting at 2 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by Regional Cardiology Center, The Copper Health Centre (MCZ), · Observational

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Angina Pectoris with a site in Poland — 3 open to participants now, 6 under way, none of them phase 3. Angina Pectoris · Poland.

Started
2022
with 1 other
Observational
Only one
of the 13
Registered
10th of 13
by date

Among the 13 studies in Angina Pectoris with a site in Poland, this one is one of 2 that started in 2022, is the only observational one, and was the 10th registered.

Angina Pectoris

454 studies on the registry are indexed under Angina Pectoris; 67 are open to participants now.

Browse Angina Pectoris studies →

Open to participants now

3 of the 13 studies in Angina Pectoris with a site in Poland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 46 Angina Pectoris studies recruiting now, 34 (74%) set no upper age limit and 1 (2%) stops at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Angina Pectoris with a site in Poland, or all of them as a file.
02

Study summary

Lower Silesia Sinus Reducer Registry is a , single-center, single-arm registry including patients with chronic disabling refractory angina pectoris (Canadian Cardiovascular Society [CCS] classes 2-4) despite maximally tolerated anti-angina medical therapy who underwent Coronary Sinus Reducer implantation .

Read the detailed description

Lower Silesia Sinus Reducer Registry is a single-center, single-arm registry including all consecutive patients who were referred to the Cardiac Department of Copper Health Center due to chronic disabling refractory angina pectoris (Canadian Cardiovascular Society [CCS] classes 2-4) despite maximally tolerated anti-angina medical therapy and underwent Coronary Sinus Reducer implantation. All patients were evaluated by the local Heart Team and considered not amenable to percutaneous or surgical revascularization procedures. After the Heart Team evaluation patients were qualified for the procedure or Coronary Sinus Reducer implantation unless they met one of the exclusion criteria.

Initial patient evaluation (prior to device implantation) consisted of past medical history, actual clinical assessment with an evaluation of CCS class, Seattle Angina Questionnaire - 7 items (SAQ-7) scores, 6-min walk distance (6-MWT) test, and echocardiography. First, a follow-up visit was scheduled 1 month after the implantation procedure.The study will include clinical assessments every six months during an observation period. The primary outcomes will be gathered one year after the implantation of the CS. Nevertheless, clinical follow-up will continue for up to five years after the procedure.

03

Conditions studied

  • Safety Issues
  • Efficacy, Self

Browse trials for

Keywords

  • Coronary Sinus Reducer
  • Refractory angina
  • Chronic coronary artery diseases (CAD)
  • Non-obstructive Coronary artery diseases (CAD)
  • Coronary microvascular dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of subjects with chronic disabling refractory angina pectoris (Canadian Cardiovascular Society [CCS] classes 2-4) who have not responded to treatment with maximally tolerated anti-angina medical therapy. The local Heart Team will evaluate all patients and determine that they are not suitable for percutaneous or surgical revascularization procedures. Following the Heart Team evaluation, patients who do not have any revascularization options available to them are eligible for the procedure or Coronary Sinus Reducer implantation, unless they meet one of the exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. present of chronic disabling angina pectoris (Canadian Cardiovascular Society [CCS] classes 2-4) despite maximally tolerated anti-angina medical therapy
  2. Heart team evaluation with consideration of ineligibility for percutaneous or surgical revascularization procedures.

Exclusion criteria

Exclusion Criteria:

  1. recent acute coronary syndrome (\<3 months),
  2. recent coronary revascularization (\<3 months)
  3. a mean right atrial pressure higher than 15 mm Hg
  4. coronary sinus proximal diameter \<10mm and >14mm
  5. under 12 months,
  6. advanced heart failure ( [NYHA] Classification - classes 3-4),
  7. potential implantable cardiac resynchronization therapy defibrillator (CRT-D) implantation candidate.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Coronary Sinus Reducer implantation

    Subject after Coronary Sinus Reducer implantation due to chronic disabling refractory angina pectoris (Canadian Cardiovascular Society \[CCS\] classes 2-4) despite maximally tolerated anti-angina medical therapy. All patients were evaluated by the local Heart Team and considered not amenable to percutaneous or surgical revascularization procedures. After the Heart Team evaluation patients were qualified for the procedure or Coronary Sinus Reducer implantation unless they meet one of the exclusion criteria. Initial patient evaluation (prior to device implantation) consists of past medical history, actual clinical assessment with an evaluation of CCS class, Seattle Angina Questionnaire - 7 items (SAQ-7) scores, 6-min walk distance (6-MWT) test, and echocardiography. First, a follow-up visit is scheduled 1 month after the implantation procedure than the follow-up is planned twice a year.

    Device: Coronary Sinus Reducer Implantation

Interventions

  • DeviceCoronary Sinus Reducer Implantation

    Coronary Sinus (CS) Reducer implantation to coronary sinus via the venous system. Coronary Sinus is a balloon-expandable, hourglass-shaped, scaffold implanted percutaneously into the coronary sinus creating a narrowing to delay blood outflow.

06

What researchers measure

Primary outcomes

  1. The Clinical success - reduction of angina symptoms

    The severity of angina is assessed by the Canadian Cardiovascular Society Scale (CCS) class, which ranges from grade I to IV. A higher CCS grade indicates a greater severity of angina.

    Time frame: 1-Year after implantation

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Safety outcomes were defined as procedural final serious complications (perforation, abrupt closure, slow flow or no-reflow, unstable ventricular arrhythmias) and device failure (inability to cross coronary sinus, inability to expand; unplanned relocation of the device)

    Time frame: 1-Year after implantation

  2. Change in potential aerobic capacity and endurance - The six minute walking test (6MWT)

    Change in subjects aerobic capacity and endurance will be assessed using The six minute walking test (6 MWT)- The longer the distance covered, the better the exercise tolerance

    Time frame: 1-Year after implantation

  3. Reducing the severity of angina and it impact on quality of life, as shown by the Seattle Angina Questionnaire.

    Potential physical and quality of life limitations will be assessed using Seattle Angina Questionnaire-7 (SAQ-7). Summary score can best be understood by categorizing the scores into ranges: 0 to 24 represents poor health status, 25 to 49 as fair, 50 to 74 as good, and 75 to 100 as excellent.

    Time frame: 1-Year after implantation

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Wlodarczak S, Rola P, Jastrzebski A, Woitek F, Barycki M, Furtan L, Doroszko A, Wlodarczak A, Grygier M, Lesiak M. Coronary Sinus Reducer implantation in refractory angina: Short-term outcomes based on the Lower Silesia Sinus Reducer Registry (LSSRR). Kardiol Pol. 2023;81(5):508-511. doi: 10.33963/KP.a2023.0057. Epub 2023 Mar 5. No abstract available. PubMed 36871301 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for May 2027, 60 months after the start.

Of 44 non-industry observational studies under Angina Pectoris, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 86. This study's planned 60 months is above that.

Counting every sponsor, half of 68 studies reached it within 34 months; a quarter within 19 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2024
First posted
Mar 1, 2024
StartActual
May 11, 2022
Primary completionEst.
May 11, 2027
CompletionEst.
May 11, 2027
Last update
Mar 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06288165
Lead sponsor
Regional Cardiology Center, The Copper Health Centre (MCZ),
Responsible party
Adrian Włodarczak (Profesaor, Regional Cardiology Center, The Copper Health Centre (MCZ),) — Principal investigator
First posted
Mar 1, 2024
Start date
May 11, 2022
Primary completion
May 11, 2027 (estimated)
Completion
May 11, 2027 (estimated)
Last update
Mar 1, 2024

Study contacts

Adrian Włodarczak, Prof.
Contact
wlodarczak.adrian@gmail.com
0048768460-285
Szymon Włodarczak, MD
Contact
wlodarczak.szy@gmail.com
0048 693-350-846

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion